Shows
The Profound IdiotsJack Benny Goes Broadway AND Bust - Part TwoBack in Hollywood fresh from being overlooked by Broadway, Jack hosts his own version of "Waiting For Godot" on his television program so the world can finally see what a great theatrical impresario he thinks he is.
With special guests stars Humphrey Bogart and Cary Grant.
Written and performed by Jack West.2023-03-1210 min
The Profound IdiotsJack Benny Goes Broadway AND Bust - Part OneWhat? MORE Jack Bennyistic romps? Yikes!
Jack Benny tries to land the lead role in what's being hailed as "the Greatest Play Sensation of the Century" so he can show the world what a great actor he thinks he is.
With special guest stars Ronald Colman, Burns & Allen, Marlene Dietrich and Fred Allen.
Written and performed by Jack West.
Based on an idea by Brad Strickland.2023-03-1021 min
The Profound IdiotsThe Jack Benny "A Christmas Carol" ShowWritten and performed by Jack West.
The great radio comedian's classic Christmas episode -- that never was. In this one-man performance, Jack West serves up a riotous rendition on what we can only imagine could have been Jack Benny's twist on the Dickens' novella. Adapting material and routines from the Jack Benny radio program with new material by Mr. West, the old miser (Ebenezer Benny, that is) spends Christmas Eve with Benny regular zanies Mary Livingstone, Don Wilson, Eddie "Rochester" Anderson, Dennis Day, Mel Blanc, Frank Nelson and Sheldon Leonard along with special guest stars Boris Karloff...2023-03-0841 min
The Profound IdiotsOPERATION CLUTTERBUCKFantasy comedy. Inspired by a true event. The rest? Completely made up! I said it was a fantasy, remember?
During World War II, Royal Navy Intelligence Officer Ian Fleming along with Prime Minister Winston Churchill hatch a plot to cast a spell on Hitler... with the help of British witches.
Starring Karen Corrado, Laura Mirsky and Jack West.
Music Traditional. Additional Music by Kevin MacLeod.
Written and directed by Jack West.
A production from The Profound Idiots.2023-01-091h 19
The Profound IdiotsTHE MAN WHO KNOWED TOO MUCHThe Profound Idiots bring you their irreverent spoof of Alfred Hitchcock's suspense thriller, "The Man Who Knew Too Much" starring James Stewart and Doris Day. Which means, if you've been waiting to hear a parody of it, you've been waiting since 1956.
An American couple and their little boy vacation in Morocco when a chance encounter with a mysterious Frenchman turns their lives upside down. The Frenchman is murdered in the marketplace and dies revealing that an international assassination is to take place in London and to inform the police to investigate "Ambrose Chappell." Their boy is abducted...2022-08-271h 22
The Profound IdiotsCANTERVILLE'S GHOSTS Episode 7: "What a Day for a Die Hard"The series finale!
The one where Quinn saves the world. Maybe. And, yippe-ki-yea!
Created and written by Jack West.
Starring Jack West, Karen Corrado and Lisa Rudin.
Music by Kevin MacLeod.
Additional music by Jason Shaw.2021-10-2422 min
The Profound IdiotsCANTERVILLE'S GHOSTS Episode 6: "The Curious Case Of The Sacrilegious Monk"In which Quinn has to make a split decision. The world's fate hangs in the balance. Things are getting to a boil.
Which means someone's going off half-baked.
Sci-fi sitcom. Created and written by Jack West.
Starring Jack West, Karen Corrado and Lisa Rudin.
Music by Kevin MacLeod.
2021-09-2727 min
The Profound IdiotsCANTERVILLE'S GHOSTS Episode 5: "Could This Be The End Of Quinn Canterville?"It's any which way but up as Quinn gets it from everyone.
Created and written by Jack West.
Starring Jack West, Karen Corrado, Lisa Rudin and Bill Barry.
Music by Kevin MacLeod.2021-08-1730 min
The Profound IdiotsCANTERVILLE'S GHOSTS Episode 4: "May The Best Man Win"The ghost hunting competition heats up in crazy ways.
Created and written by Jack West.
Starring Jack West and Karen Corrado.
Music by Kevin MacLeod.
"Volare" by Domenico Modugno and Franco Migliacci. 2021-07-1332 min
The Profound IdiotsCANTERVILLE'S GHOSTS Episode 3: "X-Points The Spot"Quinn and Sylvie look for Nick... somewhere in some dimension. It's adventure time with her new invention. If it works. And watch out, Mackie's in town.
Written by Jack West.
Starring Jack West and Karen Corrado.
Music by Kevin MacLeod.2021-06-3031 min
The Profound IdiotsCANTERVILLE'S GHOSTS Episode 2: "Abra Cadaver!"On location at the Elizabeth Borden Hospital for the Criminally Insane for the ghost-hunting TV reality show, Quinn, Sylvie and Nick try to find out the identity of the mysterious killer ghost.
Created and Written by Jack West.
Starring Jack West and Karen Corrado.
Music by Kevin MacLeod.
2021-06-1638 min
The Profound IdiotsCANTERVILLE'S GHOSTS Episode 1: "Little Donut Shop Of Horrors"A fantasy thriller comedy. The world's most inept detective lands up in a reality ghost-hunting show he thinks is faked - but the ghost is very real. And deadly.
In this first episode, when a successful old rival shows up, the world’s most incompetent detective, Quinn Canterville, sets out to show him up by faking a ghost haunting. In the process he provokes a native tribe into protesting, their litigious lawyer to sue, a mob of angry priests to descend on the scene and nearly drives his client to bankruptcy. What could possibly go wrong?
...2021-04-2328 min
The Profound IdiotsIf Jack Benny Did "A Christmas Carol" It Might Go Something Like ThisThe great radio comedian's classic Christmas episode - that never was. With Boris Karloff, Peter Lorre, Humphrey Bogart, Cary Grant, George Jessel, Eddie "Rochester" Anderson, Mel Blanc, Frank Nelson and Mary Livingstone voiced by Jack West and Karen Corrado. Written by Jack West.2020-12-2035 min
The Profound IdiotsThe Odd Couple - Rudolph The Red-Nosed Reindeer (Parody)Imagine if "The Odd Couple" - Oscar Madison (Walter Matthau) and Felix Ungar (Jack Lemmon) - squabbled about "Rudolph the Red-Nosed Reindeer," how would it go? In the spirit of Neil Simon, we think it would sound something like this!
Written by and starring Jack West. 2020-11-2205 min
The Profound IdiotsGhosts From The WellThis is NOT the Abbott & Costello movie, "The Times Of Their Lives" but rather a re-imagining. Two people mistaken for traitors during the American Revolutionary War are doomed by a curse to be bound to earth forever. Their ghosts now haunt a married couple on Long Island, NY. When an eccentric ghost hunter and his odd, clairvoyant assistant are brought in to rid the home of the spirits, the ghost hunter’s mistaken for an old nemesis, there’s a wacky séance - and big problems.
Written by Jack West.
Performed by Jack West and Karen C...2020-08-071h 20
West Wind (Audio)Drs. Jack West and Charu Aggarwal: New Data on Liquid Biopsies, Tumor Mutational Burden, and Choosing Optimal Systemic Therapy TodayDr. Charu Aggarwal from University of Pennsylvania Abramson Cancer Center joins Dr. Jack West to discuss new data on plasma-based testing for tumor mutational burden (TMB) & the current state of liquid biopsies, TMB, & immunotherapy-based options today.2020-03-0936 min
The BeaconDrs. Jack West and Charu Aggarwal: New Data on Liquid Biopsies, Tumor Mutational Burden, and Choosing Optimal Systemic Therapy TodayDr. Charu Aggarwal from University of Pennsylvania Abramson Cancer Center joins Dr. Jack West to discuss new data on plasma-based testing for tumor mutational burden (TMB) & the current state of liquid biopsies, TMB, & immunotherapy-based options today.2020-03-0936 min
West Wind (Audio)Dr. Jack West: Exploring and Explaining the Shortcomings in Molecular Testing and Execution of Targeted TherapyHost Jack West reviews the gulf between the best evidence-based cancer care guidelines & performance in broad clinical practice, exploring contributing factors & potential new models to improve US-based molecular oncology practice.2020-02-2423 min
The BeaconDr. Jack West: Exploring and Explaining the Shortcomings in Molecular Testing and Execution of Targeted TherapyHost Jack West reviews the gulf between the best evidence-based cancer care guidelines & performance in broad clinical practice, exploring contributing factors & potential new models to improve US-based molecular oncology practice.2020-02-2423 min
West Wind (Audio)Dr. Jack West on New Data Combining Radiation with Immunotherapy in Advanced NSCLC: A Brief Critical ReviewDr. Jack West provides a brief summary of key findings & limitations of two new papers just out in JAMA Oncology (Theelen et al & Bauml et al.) that evaluate the potential benefit of preceding immunotherapy with radiation in patients with advanced NSCLC.2019-07-1518 min
West Wind (Video)Dr. Jack West on New Data Combining Radiation with Immunotherapy in Advanced NSCLC: A Brief Critical ReviewDr. Jack West provides a brief summary of key findings & limitations of two new papers just out in JAMA Oncology (Theelen et al & Bauml et al.) that evaluate the potential benefit of preceding immunotherapy with radiation in patients with advanced NSCLC.2019-07-1518 min
The BeaconDr. Jack West on New Data Combining Radiation with Immunotherapy in Advanced NSCLC: A Brief Critical ReviewDr. Jack West provides a brief summary of key findings & limitations of two new papers just out in JAMA Oncology (Theelen et al & Bauml et al.) that evaluate the potential benefit of preceding immunotherapy with radiation in patients with advanced NSCLC.2019-07-1518 minThe BeaconDr. Jack West on New Data Combining Radiation with Immunotherapy in Advanced NSCLC: A Brief Critical ReviewDr. Jack West provides a brief summary of key findings & limitations of two new papers just out in JAMA Oncology (Theelen et al & Bauml et al.) that evaluate the potential benefit of preceding immunotherapy with radiation in patients with advanced NSCLC.2019-07-1500 min
The BeaconDr. Jack West: Why the Broader FDA Approval of First Pembrolizumab Monotherapy based on KEYNOTE-042 is an Invitation to Inferior Care in Advanced NSCLCDr. Jack West reviews why the new FDA approval of first line pembrolizumab monotherapy for the 1-49% PD-L1 subgroup won on a technicality and now offers a clearly inferior choice compared to far better existing standards for patients with low tumor PD-L1.2019-04-1920 min
The BeaconDr. Jack West: Why the Broader FDA Approval of First Pembrolizumab Monotherapy based on KEYNOTE-042 is an Invitation to Inferior Care in Advanced NSCLCDr. Jack West reviews why the new FDA approval of first line pembrolizumab monotherapy for the 1-49% PD-L1 subgroup won on a technicality and now offers a clearly inferior choice compared to far better existing standards for patients with low tumor PD-L1.2019-04-1900 min
West Wind (Audio)Dr. Jack West: Why the Broader FDA Approval of First Pembrolizumab Monotherapy based on KEYNOTE-042 is an Invitation to Inferior Care in Advanced NSCLCDr. Jack West reviews why the new FDA approval of first line pembrolizumab monotherapy for the 1-49% PD-L1 subgroup won on a technicality and now offers a clearly inferior choice compared to far better existing standards for patients with low tumor PD-L1.2019-04-1920 minWest Wind (Video)Dr. Jack West: Why the Broader FDA Approval of First Pembrolizumab Monotherapy based on KEYNOTE-042 is an Invitation to Inferior Care in Advanced NSCLCDr. Jack West reviews why the new FDA approval of first line pembrolizumab monotherapy for the 1-49% PD-L1 subgroup won on a technicality and now offers a clearly inferior choice compared to far better existing standards for patients with low tumor PD-L1.2019-04-1920 min
The BeaconDr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the evidence on an optimal duration of immunotherapy for long-responding patients with advanced NSCLC, weighing efficacy, potential toxicity, and cost concerns.2019-03-0820 min
The BeaconDr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074)Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the challenges of conducting clinical trials and delivering increasingly complex patient care, along with the possible future role of artificial intelligence and telemedicine.2019-03-0524 min
The BeaconTop 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter.2018-12-2813 min
The BeaconWhat does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)Dr. Jack West reviews the trial design, key results, and implications of the CheckMate-331 trial of nivolumab (Opdivo) vs. standard chemotherapy for relapsed small cell lung cancer.2018-12-2108 min
The BeaconThe IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)Dr. Jack West reviews the IMpower130 trial of carboplatin + nab-paclitaxel with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and whether this positive trial changes management in this setting.2018-12-1109 min
The BeaconOverall Survival Benefit for Local Ablative Therapy as Consolidation for Oligometastatic Stage IV NSCLC: Where Does it Fit in Practice Now? (BMIC-070)Dr. Jack West describes recently updated results of a small randomized trial of consolidation local ablative therapy (LAT) for oligometastatic advanced NSCLC after initial systemic therapy & considers whether these results should shape clinical practice.2018-12-0909 min
The BeaconThe IMpower132 Trial: Does This Change the Advanced NSCLC Landscape? (BMIC-069)Dr. Jack West reviews the IMpower132 trial of platinum + pemetrexed with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and where these results fit into management of patients in this setting.2018-12-0406 min
The BeaconThe MYSTIC Trial has Failed on Overall Survival in Advanced NSCLC: What Does and Doesn't This Tell Us? (BMIC-068)Dr. Jack West reviews the trial design of the MYSTIC trial of durvalumab alone or in combination with tremelimumab, what we know about results, and the implications for the current & future landscape in NSCLC.2018-12-0209 min
The BeaconPembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with advanced NSCLC performance status (PS) of 2, which demonstrated favorable efficacy and no concerning challenges with toxicity in this population.2018-11-1604 min
The BeaconLong-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)Dr. Jack West reviews longitudinal outcomes for patients on the KEYNOTE-010 trial of pembrolizumab (Keytruda) vs. docetaxel as 2nd line therapy for advanced NSCLC, with helpful new info on those completing 2 years of pembro & implications for practice.2018-11-1408 min
The BeaconUpdated Results on PACIFIC Trial: Should we Revise Who Should Receive Consolidation Immunotherapy after Chemo/Radiation? (BMIC-065)Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiation for unresectable stage III NSCLC and highlights new data on overall survival and the different results in patient subgroups.2018-11-0807 min
The BeaconIMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)Dr. Jack West reviews the IMpower133 trial that integrated atezolizumab with first line chemo for extensive stage SCLC and discusses whether the results improve outcomes enough to change our standard of care in this setting.2018-11-0607 min
The Beacon"Best Treatment First": Implications for front-Loading Combinations in Lung Cancer (BMIC-063)Dr. Jack West describes an emerging theme that the best outcomes for patients with lung cancer and likely other cancer are best served by receiving the best agents up front, a strategy that implies a value in integrating more treatments into early combos.2018-09-0709 min
The BeaconLocal Therapy for Advanced NSCLC: Revising Outdated Principles for Selected Patients (BMIC-062)Dr. Jack West reviews general principles for how local therapies are increasingly appropriate for selected patients with advanced NSCLC, whether at initial management, for limited progression on systemic therapy, or as local consolidation therapy.2018-09-0415 min
The BeaconHow do Patients with Advanced NSCLC on Daily Steroids Do on Immune Checkpoint Inhibitors? (BMIC-046)Dr. Jack West summarizes findings of a retrospective analysis from Dr. Arbour of MSKCC, evaluating the clinical outcomes of patients with advanced NSCLC on daily steroids while receiving an immune checkpoint inhibitor against PD-1 or PD-L1.2018-07-1209 min
The BeaconIs Chemo the Key to the Best Combination for EGFR Mutation-Positive NSCLC? The Data Too Good to Overlook (BMIC-045)Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination of carboplatin/pemetrexed with gefitinib as initial therapy compared to gefitinib followed by chemotherapy in patients with EGFR mutation-positive advanced NSCLC.2018-07-0912 min
The BeaconIs the Survival Benefit from Dacomitinib on the ARCHER-1050 Trial Enough to Make it a Contender as First Line Treatment for EGFR Mutation-Positive NSCLC Today? (BMIC-044)Dr. Jack West reviews results from ARCHER-1050, a trial of dacomitinib vs. gefitinib, in EGFR mutation-positive NSCLC, asks whether the demonstrated survival benefit is enough to make dacomitinib a player as first line treatment.2018-07-0507 min
The BeaconThe Erlotinib/Bevacizumab Combination in EGFR Mutation-Positive Advanced NSCLC: Is Progression-Free Survival without Overall Survival Benefit Enough? (BMIC-043)Dr. Jack West discusses results and the significance of two important Japanese trials that test the combination of erlotinib (Tarceva) with bevacizumab (Avastin), which shows a consistent improvement in progression-free survival but not overall survival.2018-07-0210 min
The BeaconSmall Trial Shows Big Risks of Giving First Line Pembrolizumab to EGFR Mutation-Positive Patients, Even with High Tumor PD-L1 Expression (BMIC-042)Dr. Jack West summarizes a small trial from UCLA that tests the utility of giving first line immunotherapy to EGFR mutation-positive patients with high tumor PD-L1 expression, which led to poor outcomes that should cast a long shadow on this approach.2018-06-2807 min
The BeaconIMpower131: What is the Role for the Carbo/Nab-Paclitaxel/Atezolizumab Combination for Advanced Squamous NSCLC? (BMIC-041)Dr. Jack West summarizes key data from the IMpower131 trial of patients with advanced squamous NSCLC & examines whether the carboplatin/nab-paclitaxel/atezolizumab combination is a strong treatment option in this patient setting.2018-06-2508 min
The BeaconIs Nivo/Ipi the Treatment of Choice for Patients with Advanced NSCLC, Tumor PD-L1 Less Than 1%, & High TMB? New Data from CheckMate 227 (BMIC-040)Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 2018-06-2208 min
The BeaconKEYNOTE-407: Practice-Changing Positive Trial for Advanced Squamous NSCLC (BMIC-039)Dr. Jack West reviews KEYNOTE-407, first line chemo/immunotherapy with pembrolizumab vs. chemo alone in advanced squamous NSCLC, which demonstrated a significant survival benefit that should change practice in this setting.2018-06-2009 min
The BeaconKEYNOTE-042: Should Pembrolizumab Replace Chemo for a Broader Population of Patients with Advanced NSCLC? (BMIC-038)Dr. Jack West reviews the KEYNOTE-042 trial of pembrolizumab vs. chemo in PD-L1-positive NSCLC, highlighting key findings from the presentation in the Plenary Session at ASCO 2018, clinical implications, & whether it should change practice.2018-06-1811 min
The BeaconMy Top 5 ASCO 2018 Abstracts in Stage I-III NSCLC, Small Cell Lung Cancer, & Mesothelioma (BMIC-037)Dr. Jack West reviews his top 5 abstracts in stage I-III non-small cell lung cancer, small cell lung cancer, and mesothelioma at ASCO 2018, explaining why each is poised to change the landscape of patient care in this setting.2018-05-2307 min
The BeaconMy Top 5 ASCO 2018 Abstracts in Advanced NSCLC (BMIC-036)Dr. Jack West reviews his top 5 abstracts in the advanced NSCLC track at ASCO 2018, explaining why each is poised to change the landscape of patient care in this setting.2018-05-2110 min
The BeaconAre Tumor Mutation Burden and Nivolumab/Ipilimumab Ready for Clinical Use? Insights from CheckMate 227 (BMIC-035)Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB).2018-05-1109 min
The BeaconNivolumab/Ipilimumab vs. Chemo in High TMB Advanced NSCLC: Key Results from CheckMate 227 (BMIC-034)Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB).2018-05-1013 min
The BeaconKEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Negative (sub 1%) Tumor PD-L1 Expression (BMIC-033)Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and negative (2018-05-0406 min
The BeaconKEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Low (1-49%) Tumor PD-L1 Expression (BMIC-032)Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and low (1-49%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset.2018-05-0406 min
The BeaconKEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and High (≥50%) Tumor PD-L1 Expression (BMIC-031)Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and high tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of these patients.2018-04-3007 min
The BeaconKEYNOTE-189: Key Summary of a Practice-Changing Trial in Advanced Non-Squamous NSCLC (BMIC-030)Dr. Jack West reviews the trial design, efficacy endpoints, and toxicity results of the KEYNOTE-189 trial of pembrolizumab or placebo added to cisplatin or carboplatin with pemetrexed chemo in advanced non-squamous NSCLC with any PD-L1 expression.2018-04-2713 min
The BeaconIs Chemotherapy More Effective After Prior Immunotherapy? (BMIC-029)Dr. Jack West presents early data suggesting that chemotherapy may be more effective after prior immunotherapy than otherwise.2018-04-1205 min
The BeaconNew Insights on Acquired Resistance to Immune Checkpoint Inhibitors for NSCLC: Implications for Treatment Options (BMIC-028)Dr. Jack West reviews new data on patterns of acquired resistance after a response to immune checkpoint inhibitors for advanced NSCLC, along with the clinical implications of various options based on these observations.2018-04-1011 min
The BeaconIs immunotherapy ineffective in patients with driver mutation-positive advanced NSCLC? Time to walk that back. (BMIC-027) Dr. Jack West summarizes the evolving data shaping our understanding of the role of immune checkpoint inhibitors for patients with EGFR- or ALK-positive advanced NSCLC, including more recent data that should change our perspective.2018-04-0610 min
The BeaconChemo/Immunotherapy in Advanced Squamous NSCLC: What is the Impact of IMpower131? (BMIC-026) Dr. Jack West reviews the preliminary positive result form the IMpower131 trial of chemo +/- atezolizumab immunotherapy and considers what the clinical significance of these findings should be for patients with advanced squamous NSCLC.2018-04-0409 min
The BeaconIs Durvalumab (Imfinzi) in Stage III NSCLC Curing Patients or Just Treating Metastatic Disease Earlier? Importance of Overall Survival and Implications for Duration of Treatment (BMIC-025)Dr. Jack West explores the importance of following the overall survival of patients on the PACIFIC trial and considers still open questions of whether consolidation durvalumab (Imfinzi) in stage III unresectable NSCLC should be discontinued after a year.2018-02-2206 min
The BeaconDurvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Should It Become Standard of Care Without Overall Survival Benefit Demonstrated? (BMIC-024)Dr. Jack West reviews key results of the PACIFIC trial of the immunotherapy agent durvalumab (Imfinzi) vs. placebo in stage III NSCLC and explains the pros and cons of durvalumab as a new standard of care after concurrent chemoradiation.2018-02-2007 min
GRACEcast Radiation Oncology VideoCan we safely combine Tarceva with brain radiation for lung cancer with brain radiation?Dr. Jack West describes a case series that illustrates the safety of giving whole brain radiation along with concurrent Tarceva (erlotinib) for patients with lung cancer and brain metastases.2013-02-0803 min
GRACEcast Cancer 101 VideoThanks so much for your support in 2012: Here's to a great 2013!Dr. Jack West thanks the GRACE community for their generous support in our recent Annual Appeal and offers his wishes for a happy and healthy 2013.2013-01-0303 min
GRACEcast Cancer 101 VideoHappy Holidays from Dr West and GRACEDr. Jack West wishes the cancer community a happy holiday season from GRACE.2012-12-2502 min
GRACEcast Cancer 101 VideoUsing Telemedicine to Deliver Optimal Subspecialty Care Across Healthcare NetworksDr. Jack West describes a potentially efficient way to improve delivery of increasingly specialized care to broad geographic areas by collaboration of healthcare network teams using telemedicine solutions currently available.2012-12-1905 min
GRACEcast Cancer 101 VideoDo we need to do repeat biopsies with disease progression?Dr. Jack West discusses the pros and cons of repeat biopsies of tumors in the setting of "acquired resistance" to targeted therapies, with a specific consideration of whether this should be considered a standard of care.2012-12-1403 min
GRACEcast Cancer 101 VideoWill your oncologist be a computer algorithm?Dr. Jack West reviews the limitations of artificial intelligence applied to clinical decision-making in complex cases in oncology, and why Dr. Watson won't necessarily become the perfect oncologist.2012-12-1204 min
GRACEcast Radiation Oncology VideoIs there an alternative to brain radiation for patients with several brain metastases?Dr. Jack West reviews a case that illustrates the potential option of systemic therapy for brain metastases before initiating whole brain radiation.2012-12-0505 min
GRACEcast Cancer 101 VideoIntro to Casual Video GRACEcasts UncutDr. H. Jack West describes the new format of presenting cancer information in brief, more casual video-based format.2012-11-1602 min
GRACEcast Lung Cancer AudioShould Surgery be Considered for Very Limited Small Cell Lung Cancer? (audio)Dr. Howard (Jack) West, medical oncologist, President & CEO of GRACE, reviews the debate about whether surgery should have a role in managing early small cell lung cancer (SCLC).2010-03-3124 minGRACEcast Lung Cancer AudioThought Leader Round Table: Drs Laskin and Sandler, Part 2 (audio)Lung cancer experts Janessa Laskin and Alan Sandler sit down with medical oncologist Jack West to discuss complex cases. Focus on first line chemo standards and the transition to maintenance therapy.2010-01-1209 minGRACEcast Lung Cancer AudioThought Leader Round Table: Drs Laskin and Sandler, Part 1 (audio)Lung cancer experts Janessa Laskin and Alan Sandler sit down with medical oncologist Jack West to discuss complex cases. Focus on never-smokers and EGFR mutation testing.2010-01-0510 minGRACEcast Lung Cancer AudioCancer Lifeline Lecture - Part 3, Locally Advanced, Unresectable NSCLC (audio)This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he covers the optimal treatment strategies for locally advanced (stage III), unresectable NSCLC.2009-09-1113 minGRACEcast Lung Cancer AudioCancer Lifeline Lecture - Part 2, Adjuvant Chemo for Early Stage NSCLC (audio)This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he discusses the evidence supporting the current standard of adjuvant (post-operative) chemotherapy to improve survival for patients with early stage, resected NSCLC.2009-08-2022 minGRACEcast Lung Cancer AudioManagement Options for Stage IIIA NSCLC: The Outer Limits of Resectability (audio)This slide presentation by medical oncologist and lung cancer expert Dr. Jack West covers the most common management strategies for stage IIIA N2 node-positive NSCLC, with a particular focus on a comparison of preoperative treatment followed by surgery vs. chemo and radiation without surgery.2009-07-2009 minGRACEcast Lung Cancer AudioInterview with Dr. Sarita Dubey: Chemotherapy for Early Stage NSCLC (audio)This interview by medical oncologist Dr. Jack West of Dr. Sarita Dubey, medical oncologist at UCSF Cancer Center, covers the evidence and ongoing questions about the role of chemotherapy in early stage NSCLC.2009-07-0215 minGRACEcast Lung Cancer AudioCancer Lifeline Lecture - Part 1 SCLC (audio)This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he discusses current and investigational treatment options for relapsed small cell lung cancer, with a particular focus on amrubicin.2009-06-1710 minGRACEcast Lung Cancer AudioRamalingam on Advanced NSCLC: First Line and Maintenance Therapy (audio)This interview by medical oncologist Dr. Jack West of Dr. Suresh Ramalingam, medical oncologist at Emory University in Atlanta, covers the evolving first line treatment standards of chemotherapy and targeted therapy for the first line treatment, as well as the emerging issue of maintenance therapy after initial treatment of advanced NSCLC.2009-05-2922 minGRACEcast Lung Cancer AudioNever-Smokers with Lung Cancer: A Separate Disease? (audio)This slide presentation by medical oncologist and lung cancer expert Dr. Jack West presents a general background on the distinct demographic, pathologic, molecular, and treatment outcome features seen among never-smokers with lung cancer.2009-05-2110 min
GRACEcast Radiation Oncology VideoInterview with Raditation Oncologist Vivek Mehta: Radiation from Stage I to Stage IV NSCLC (video)This interview by medical oncologist Dr. Jack West of Dr. Vivek Mehta, radiation oncologist Seattle, includes discussion of emerging radiation techniques to treat medically inoperable early stage lung cancer, the challenges of treating locally advanced NSCLC with chemo/radiation, and the role of radiation in advanced lung cancer.2009-05-1323 minGRACEcast Radiation Oncology AudioInterview with Raditation Oncologist Vivek Mehta: Radiation from Stage I to Stage IV NSCLC (audio)This interview by medical oncologist Dr. Jack West of Dr. Vivek Mehta, radiation oncologist Seattle, includes discussion of emerging radiation techniques to treat medically inoperable early stage lung cancer, the challenges of treating locally advanced NSCLC with chemo/radiation, and the role of radiation in advanced lung cancer.2009-05-1323 minGRACEcast Lung Cancer AudioInterview with Raditation Oncologist Vivek Mehta: Radiation from Stage I to Stage IV NSCLC (audio)This interview by medical oncologist Dr. Jack West of Dr. Vivek Mehta, radiation oncologist Seattle, includes discussion of emerging radiation techniques to treat medically inoperable early stage lung cancer, the challenges of treating locally advanced NSCLC with chemo/radiation, and the role of radiation in advanced lung cancer.2009-05-1323 min
GRACEcast Cancer 101 VideoInterview with Dr. David Djang: The Role of PET Scans in Oncology (video)This interview by medical oncologist Dr. Jack West of Dr. David Djang, nuclear medicine expert in Seattle, covers the general principles and clinical utility of PET scans in lung cancer and other aspects of oncology.2009-05-0119 minGRACEcast Cancer 101 AudioInterview with Dr. David Djang; The Role of PET Scans in Oncology (audio)This interview by medical oncologist Dr. Jack West of Dr. David Djang, nuclear medicine expert in Seattle, covers the general principles and clinical utility of PET scans in lung cancer and other aspects of oncology.2009-05-0119 minGRACEcast Lung Cancer AudioTiming of Maintenance/Second Line Chemotherapy in Advanced NSCLC (audio)This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the emerging data about the controversial aspects of timing the transition from first line to second line chemotherapy for advanced non-small cell lung cancer (NSCLC).2009-04-3010 minGRACEcast Lung Cancer AudioInterview with Dr. Suresh Ramalingam: Managing Locally Advanced NSCLC (audio)This interview by medical oncologist Dr. Jack West of lung cancer expert Dr. Suresh Ramalingam from Winship Cancer Institute at Emory University reviews recent results and the changing perspective on optimal treatment of stage III, locally advanced non-small cell lung cancer (NSCLC).2009-04-0908 minGRACEcast Lung Cancer AudioChemotherapy for Second Line Treatment of Non-Small Cell Lung Cancer (NSCLC) (audio)This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the development of current standards and anticipated benefits vs. risks of second line chemotherapy for advanced non-small cell lung cancer (NSCLC).2009-03-3110 minGRACEcast Lung Cancer AudioInterview with Dr. Antonia Wozniak: Current Best Practices for Small Cell Lung Cancer (audio)This interview by medical oncologist Dr. Jack West of lung cancer expert Toni Wozniak from Karmanos Cancer Institute at Wayne State University covers current standards for optimal management of small cell lung cancer (SCLC).2009-03-1808 minGRACEcast Lung Cancer AudioThe ABC's of BAC (Bronchioloalveolar Carcinoma) (audio)This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the unique clinical, imaging, and treatment response features of advanced bronchioloalveolar carcinoma (BAC), a distinct sybtype of lung adenocarcinoma.2009-03-1113 minGRACEcast Lung Cancer AudioAn Introduction to the Pre-Op Workup and Surgical Options in Early Stage NSCLC (audio)This interview by medical oncologist Dr. Jack West of expert thoracic surgeon Eric Vallières covers the basics of the pre-operative work-up and surgical approaches for early stage non-small cell lung cancer (NSCLC).2009-03-0630 minGRACEcast Lung Cancer AudioOptimal Treatment of Unresectable Locally Advanced NSCLC (audio)This slide presentation by medical oncologist and lung cancer expert Dr. Jack West describes the evolution of our current standards for chemotherapy for the first line treatment of metastatic non-small cell lung cancer.2009-02-2810 minGRACEcast Lung Cancer AudioAntiangiogenesis in First Line NSCLC (audio)This presentation by medical oncologist and lung cancer expert Dr. Jack West introduces the concept of angiogenesis, with a focus on the combination of Avastin (bevacizumab) with chemotherapy for advanced non-small cell lung cancer (NSCLC).2009-01-3009 minGRACEcast Lung Cancer AudioJanessa Laskin Interview (audio)This interview by medical oncologist Dr. Jack West of fellow medical oncologist and lung cancer expert Dr. Janessa Laskin covers the current standards and controversial aspects of post-operative chemotherapy for resected early stage NSCLC.2009-01-2208 min
GRACEcast Radiation Oncology VideoVivek Mehta Interview (video)This interview by medical oncologist Dr. Jack West of radiation oncologist and lung cancer expert Dr. Vivek Mehta covers the current and emerging treatment options for radiation alternatives to treat early stage non-small cell lung cancer (NSCLC).2009-01-1423 minGRACEcast Radiation Oncology AudioVivek Mehta Interview (audio)This interview by medical oncologist Dr. Jack West of radiation oncologist and lung cancer expert Dr. Vivek Mehta covers the current and emerging treatment options for radiation alternatives to treat early stage non-small cell lung cancer (NSCLC).2009-01-1423 min
GRACEcast Lung Cancer AudioVivek Mehta Interview (audio)This interview by medical oncologist Dr. Jack West of radiation oncologist and lung cancer expert Dr. Vivek Mehta covers the current and emerging treatment options for radiation alternatives to treat early stage non-small cell lung cancer (NSCLC).2009-01-1323 minGRACEcast Lung Cancer AudioFirst Line Chemo for Advanced NSCLC (audio)This presentation by medical oncologist and lung cancer expert Dr. Jack West describes the evolution of our current standards for chemotherapy for the first line treatment of metastatic non-small cell lung cancer.2009-01-0809 min